The EMA recommended that NUZ-001, formerly monepantel, be granted orphan medicinal product designation to treat ALS in Europe ...

A Phase 2 trial testing oral ROCK inhibitor Bravyl in people with ALS is now fully enrolled at its highest dosing group.

Trace Neuroscience has launched in the U.S. with over $100 million in financing and a goal to develop its UNC13A-targeted ...

Columnist Kristin Neva sometimes get overwhelmed by her increasing caregiver responsibilities, but it helps her to know she's not alone.

The National Institute of Aging awarded a $7.3 million research grant for the study of NU-9 as a treatment for ...

The newly combined company will focus on moving Kadimastem's AstroRx, NLS's DOXA platform, and other therapies through ...

Mitochondrial genome mutations may be linked to ALS, per a study, opening the door for new ways to diagnosing and treating ...